Tuberculosis 2013 : 2 Tuberculosis biomarkers discovery : developments , needs , and challenges

Biomarkers are indispensable to the development of new tuberculosis therapeutics and vaccines. The most robust biomarkers measure factors that are essential to the underlying pathological process of the disease being treated, and thus can capture the full effects of many types of interventions on clinical outcomes in multiple prospective, randomised clinical trials. Many Mycobacterium tuberculosis and human biomarkers have been studied over the past decade. Present research focuses on three areas: biomarkers predicting treatment efficacy and cure of active tuberculosis, the reactivation of latent tuberculosis infection, and the induction of protective immune responses by vaccination. Many older, non-specific markers of inflammation, when considered in isolation, do not have sufficient predictive values for clinical use in tuberculosis. Although no new accurate, tuberculosis-specific biomarkers have yet been discovered, substantial progress has been made in some areas. However, the qualification of biomarkers as a surrogate for a clinical endpoint in tuberculosis is very challenging, and, for biomarkers that are non-culture-based, impossible to pursue without the availability of well characterised biobanks containing biospecimens from patients who have had adequate follow-up to establish long-term treatment outcome. We review progress in tuberculosis biomarker development and efforts being made to harness resources to meet future challenges.

[1]  G. Kaplan,et al.  Specific T cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis, Following BCG Vaccination of Newborns , 2010 .

[2]  G. Kaplan,et al.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. , 2008, The Journal of infectious diseases.

[3]  H. Okamura,et al.  Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. , 2000, American journal of respiratory and critical care medicine.

[4]  M. Gennaro,et al.  Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea. , 2006, International journal of immunopathology and pharmacology.

[5]  R. Gie,et al.  Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. , 2008, The Journal of infection.

[6]  K. Floyd,et al.  Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF Weyer, , 2013 .

[7]  R. Gie,et al.  Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  R. Wallis,et al.  Sustainable tuberculosis drug development. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  C. Immanuel,et al.  Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[10]  V. Pascual,et al.  Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy , 2012, PloS one.

[11]  M. Levin,et al.  Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART , 2006, AIDS.

[12]  J. Ellner,et al.  Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against Tuberculosis , 2002, Clinical and Vaccine Immunology.

[13]  R. Wallis,et al.  Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.

[14]  M. Levin,et al.  Novel Human In Vitro System for Evaluating Antimycobacterial Vaccines , 2004, Infection and Immunity.

[15]  M. Perkins,et al.  Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. , 2012, The Journal of infectious diseases.

[16]  O. Lantz,et al.  Antimicrobial activity of mucosal-associated invariant T cells , 2010, Nature Immunology.

[17]  R. Wallis,et al.  Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. , 2006, The Journal of infectious diseases.

[18]  A. Adegnika,et al.  Specific cytokine patterns of pulmonary tuberculosis in Central Africa. , 2011, Clinical immunology.

[19]  Prescott G Woodruff,et al.  Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. , 2011, American journal of respiratory and critical care medicine.

[20]  M. Levin,et al.  Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. , 2000, The Journal of infectious diseases.

[21]  Yuxin Dong,et al.  Antigens of Mycobacterium tuberculosis Recognized by Antibodies during Incipient, Subclinical Tuberculosis , 2005, Clinical Diagnostic Laboratory Immunology.

[22]  Marcela Henao-Tamayo,et al.  T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. , 2011, Tuberculosis.

[23]  M. Herbster,et al.  Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum , 2006, The Lancet.

[24]  W. Boom,et al.  Sputum Mycobacterium tuberculosis mRNA as a Marker of Bacteriologic Clearance in Response to Antituberculosis Therapy , 2009, Journal of Clinical Microbiology.

[25]  M. Barer,et al.  Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. , 2010, American journal of respiratory and critical care medicine.

[26]  P. D. Hart,et al.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. , 1977, British medical journal.

[27]  N. Maine,et al.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi , 1996, The Lancet.

[28]  J. Poole,et al.  Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children. , 1988, Clinical and experimental immunology.

[29]  R. Sorensen,et al.  Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. , 1992, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[30]  Nicole A. Kruh,et al.  Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis‐infected and culture filtrate protein‐treated macrophages , 2010, Proteomics.

[31]  M. Jacobsen,et al.  SOCS3 promotes interleukin-17 expression of human T cells. , 2012, Blood.

[32]  Dirk Repsilber,et al.  Biomarkers of Inflammation, Immunosuppression and Stress Are Revealed by Metabolomic Profiling of Tuberculosis Patients , 2012, PloS one.

[33]  D. Sack,et al.  Use of Antibodies in Lymphocyte Secretions for Detection of Subclinical Tuberculosis Infection in Asymptomatic Contacts , 2004, Clinical Diagnostic Laboratory Immunology.

[34]  R. Hussain,et al.  Dynamic Changes in Biomarker Profiles Associated with Clinical and Subclinical Tuberculosis in a High Transmission Setting: A Four‐Year Follow‐Up Study , 2009, Scandinavian journal of immunology.

[35]  K. Higuchi,et al.  Interferon‐γ responses after isoniazid chemotherapy for latent tuberculosis , 2008, Respirology.

[36]  A. Gandhe,et al.  Host biomarkers of clinical relevance in tuberculosis: review of gene and protein expression studies , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[37]  G. Vanham,et al.  Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. , 1999, The Journal of infectious diseases.

[38]  S. Niemann,et al.  Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. , 2008, American journal of respiratory and critical care medicine.

[39]  R. Adegbola,et al.  8. INTERFERON GAMMA ELISPOT AS A BIOMARKER OF TREATMENT EFFICACY IN LATENT TUBERCULOSIS INFECTION: A RANDOMIZED, BLINDED AND PLACEBO CONTROLLED CLINICAL TRIAL , 2012 .

[40]  D. Alling,et al.  The after-history of pulmonary tuberculosis. VI. The first fifteen years following diagnosis. , 1960, The American review of respiratory disease.

[41]  K. Lai,et al.  Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy. , 1995, The European respiratory journal.

[42]  J. Ellner,et al.  Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. , 2002, The Journal of infectious diseases.

[43]  K. Higuchi,et al.  Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. , 2008, Tuberculosis.

[44]  Olaf Tietje,et al.  Volatile biomarkers of pulmonary tuberculosis in the breath. , 2007, Tuberculosis.

[45]  J. Parner,et al.  The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[46]  R. Diel,et al.  Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. , 2012, Chest.

[47]  M. Perkins,et al.  Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. , 1999, American journal of respiratory and critical care medicine.

[48]  Bouke C. de Jong,et al.  Identification of Probable Early-Onset Biomarkers for Tuberculosis Disease Progression , 2011, PloS one.

[49]  Robert J Wilkinson,et al.  A single dose of vitamin D enhances immunity to mycobacteria. , 2007, American journal of respiratory and critical care medicine.

[50]  D. Mitchison Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. , 1993, The American review of respiratory disease.

[51]  M. Barreto,et al.  Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial , 2005, The Lancet.

[52]  A. Matteelli,et al.  Early tuberculosis treatment monitoring by Xpert® MTB/RIF , 2012, European Respiratory Journal.

[53]  M. Perkins,et al.  Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. , 1998, The Journal of infectious diseases.

[54]  A. Cooper,et al.  Cell-mediated immune responses in tuberculosis. , 2009, Annual review of immunology.

[55]  O. Burghuber,et al.  Peripheral T Cell Cytokine Responses for Diagnosis of Active Tuberculosis , 2012, PloS one.

[56]  T. Eguale,et al.  Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients , 2002, Journal of Clinical Microbiology.

[57]  S. Niemann,et al.  Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. , 2011, American journal of respiratory and critical care medicine.

[58]  Alimuddin Zumla,et al.  Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice , 2010, The Lancet.

[59]  C. Di Serio,et al.  A Genome-Wide Identification Analysis of Small Regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and Conservation Analysis , 2012, PloS one.

[60]  F. Demiröz,et al.  sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[61]  P. V. van Helden,et al.  Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment , 2011, Journal of Clinical Microbiology.

[62]  M. Perkins,et al.  A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. , 2011, American journal of respiratory and critical care medicine.

[63]  S. Chambers,et al.  The scent of Mycobacterium tuberculosis. , 2008, Tuberculosis.

[64]  M. Herbster,et al.  Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum , 2006, The Lancet.

[65]  P. V. van Helden,et al.  Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy , 2006, Clinical and experimental immunology.

[66]  Z. Toossi,et al.  Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. , 2001, The Journal of infectious diseases.

[67]  Dirk Repsilber,et al.  Correction: Biomarkers of Inflammation, Immunosuppression and Stress with Active Disease Are Revealed by Metabolomic Profiling of Tuberculosis Patients , 2012, PLoS ONE.

[68]  K. Dheda,et al.  Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients , 2012, European Respiratory Journal.

[69]  M. Perkins,et al.  Predicting the outcome of therapy for pulmonary tuberculosis. , 2000, American journal of respiratory and critical care medicine.

[70]  A. I. Imani Fooladi,et al.  Comparison of smear microscopy, culture, and real-time PCR for quantitative detection of Mycobacterium tuberculosis in clinical respiratory specimens , 2013, Scandinavian journal of infectious diseases.

[71]  C. Nacy,et al.  Early bactericidal activity of new drug regimens for tuberculosis , 2013, The Lancet.

[72]  John L. Johnson,et al.  Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. , 2012, Tuberculosis.

[73]  F Doucet-Populaire,et al.  (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[74]  M. Brennan,et al.  Tuberculosis vaccines: a strategic blueprint for the next decade. , 2012, Tuberculosis.

[75]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[76]  Qian Gao,et al.  Comparative miRNA Expression Profiles in Individuals with Latent and Active Tuberculosis , 2011, PloS one.

[77]  G. Besra,et al.  Biogenesis of the mycobacterial cell wall and the site of action of ethambutol , 1995, Antimicrobial agents and chemotherapy.

[78]  J. Ellner,et al.  A whole blood bactericidal assay for tuberculosis. , 2001, The Journal of infectious diseases.

[79]  Alimuddin Zumla,et al.  Immunological biomarkers of tuberculosis , 2011, Nature Reviews Immunology.

[80]  B. Vickery,et al.  An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2011, Pediatrics.

[81]  C. F. von Reyn,et al.  High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  T. Clark,et al.  Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. , 2013, The Journal of infectious diseases.

[83]  W. Boom,et al.  Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures. , 2011, Tuberculosis.

[84]  John L. Johnson,et al.  CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. , 2011, American journal of respiratory and critical care medicine.

[85]  Ho-Yeon Song,et al.  Lack of Activity of Orally Administered Clofazimine against Intracellular Mycobacterium tuberculosis in Whole-Blood Culture , 2004, Antimicrobial Agents and Chemotherapy.

[86]  R. Wallis,et al.  Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. , 2009, Tuberculosis.

[87]  M. Amicosante,et al.  Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[88]  G. Pantaleo,et al.  Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease , 2011, Nature Medicine.

[89]  G. Ippolito,et al.  Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[90]  C. Laymon,et al.  Infection Dynamics and Response to Chemotherapy in a Rabbit Model of Tuberculosis using [18F]2-Fluoro-Deoxy-d-Glucose Positron Emission Tomography and Computed Tomography , 2012, Antimicrobial Agents and Chemotherapy.

[91]  Kenneth G. C. Smith,et al.  Dendritic Cell Stimulation by Mycobacterial Hsp70 Is Mediated Through CCR5 , 2006, Science.

[92]  J. Achkar,et al.  Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. , 2011, The Journal of infectious diseases.

[93]  N. Garrett,et al.  Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study , 2012, BMC Infectious Diseases.

[94]  D. Fuchs,et al.  Neopterin, β2-Microglobulin, and Acute Phase Proteins in HIV-1-Seropositive and -Seronegative Zambian Patients with Tuberculosis , 1997, Lung.

[95]  Paul D van Helden,et al.  Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. , 2007, The Journal of infectious diseases.

[96]  Aaron S. Anderson,et al.  Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor. , 2012, Tuberculosis.

[97]  J. Ellner,et al.  Subclinical tuberculosis: a new entity? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[98]  John L. Johnson,et al.  Evaluation of Time to Detection of Mycobacterium tuberculosis in Broth Culture as a Determinant for End Points in Treatment Trials , 2010, Journal of Clinical Microbiology.

[99]  John L. Johnson,et al.  Inhibition of Isoniazid-Induced Expression of Mycobacterium tuberculosis Antigen 85 in Sputum: Potential Surrogate Marker in Tuberculosis Chemotherapy Trials , 2001, Antimicrobial Agents and Chemotherapy.

[100]  L. Aarons,et al.  Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment , 2006, Antimicrobial Agents and Chemotherapy.

[101]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[102]  Alling Dw,et al.  The after-history of pulmonary tuberculosis. IV. Far advanced tuberculosis. , 1954 .

[103]  A. Diacon,et al.  Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis , 2008, Antimicrobial Agents and Chemotherapy.

[104]  B. Eley,et al.  Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function. , 2003, The Journal of infectious diseases.

[105]  R. Balderas,et al.  Corrigendum: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[106]  R. Balderas,et al.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[107]  M. Pai,et al.  Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[108]  S. Lawn,et al.  Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria , 2012, BMC Infectious Diseases.

[109]  K. Dheda,et al.  The Diagnostic Accuracy of Urine-Based Xpert MTB/RIF in HIV-Infected Hospitalized Patients Who Are Smear-Negative or Sputum Scarce , 2012, PloS one.

[110]  Alimuddin Zumla,et al.  Biomarkers for tuberculosis disease activity, cure, and relapse. , 2009, The Lancet. Infectious diseases.

[111]  R. Diel,et al.  Interferon-&ggr; release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis , 2010, European Respiratory Journal.

[112]  S. Lawn,et al.  Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[113]  D. Mitchison,et al.  Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis , 2001, BMC pulmonary medicine.

[114]  John L. Johnson,et al.  Sputum Cytokine Levels in Patients with Pulmonary Tuberculosis as Early Markers of Mycobacterial Clearance , 2002, Clinical and Vaccine Immunology.

[115]  M. Barreto,et al.  BCG Revaccination Does Not Protect Against Leprosy in the Brazilian Amazon: A Cluster Randomised Trial , 2008, PLoS neglected tropical diseases.

[116]  D Repsilber,et al.  Human gene expression profiles of susceptibility and resistance in tuberculosis , 2011, Genes and Immunity.

[117]  Alimuddin Zumla,et al.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. , 2013, The Lancet. Infectious diseases.

[118]  Matthew S. Cook,et al.  Human Mucosal Associated Invariant T Cells Detect Bacterially Infected Cells , 2010, PLoS biology.

[119]  John L. Johnson,et al.  Whole blood bactericidal activity during treatment of pulmonary tuberculosis. , 2003, The Journal of infectious diseases.

[120]  M. Chan-yeung,et al.  Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[121]  John L. Johnson,et al.  Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. , 2008, American journal of respiratory and critical care medicine.

[122]  P. V. van Helden,et al.  Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders , 2006, Clinical and experimental immunology.

[123]  W. Rom,et al.  Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. , 1998, Chest.

[124]  G. Kaplan,et al.  Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. , 2010, American journal of respiratory and critical care medicine.

[125]  G. Scott,et al.  Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein. , 1990, The Journal of infection.

[126]  A. Rattan,et al.  Prognostic value of 'C' reactive protein in tuberculosis. , 1989, Indian pediatrics.

[127]  M. Perkins,et al.  Detection of Viable Mycobacterium tuberculosis by Reverse Transcriptase-Strand Displacement Amplification of mRNA. , 1999, Methods in molecular medicine.

[128]  Boping Zhou,et al.  Tim-3-Expressing CD4+ and CD8+ T Cells in Human Tuberculosis (TB) Exhibit Polarized Effector Memory Phenotypes and Stronger Anti-TB Effector Functions , 2012, PLoS pathogens.